19 November 2015 
EMA/850660/2015 
Procedure Management and Committees Support Division  
Statement indicating compliance with the agreed completed 
paediatric investigation plan 
Medicinal product  
ILARIS 
canakinumab 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
Route(s) of administration: 
See Annex A 
See Annex A 
Packaging and package size(s): 
See Annex A 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Novartis Europharm Ltd 
Frimley Business Park 
Camberley 
GU16 7SR 
UNITED KINGDOM 
Procedure  
Procedure number: 
EMEA/H/C/001109/II/0040/G 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and 
in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric 
investigation plan P/208/2011. For the purpose of the application of Article 45(3) of Regulation (EC) 
No 1901/2006, significant studies in the agreed paediatric investigation plan P/208/2011 have been 
completed after the entry into force of that Regulation,  
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5555 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
  
 
 
 
